Senior insider sale
Chief Operating Officer at NEWAMSTERDAM PHARMA CO N.V. — senior position signals high conviction
$9.14M
416.54K shares
KLING DOUGLAS F plans to sell 416.54K shares of NEWAMSTERDAM PHARMA CO N.V. valued at approximately $9.14M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Equity Compensation - RSU Earnout
compensation
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/26/2025 | Equity Compensation - RSU Earnout compensation | 16.54K | — |
| Total | 16.54K | ||
Completed
Units to sell
100K
Market value
$2.34M
Units to sell
9.22K
Market value
$182.9K
Units to sell
90.78K
Market value
$1.81M
Units to sell
13.58K
Market value
$289.7K
Units to sell
56.86K
Market value
$1.19M
Units to sell
25.39K
Market value
$547.9K
Units to sell
104.17K
Market value
$2.39M
Planned — Approximate Date
Units to sell
16.54K
Market value
$387.2K
Units
416.54K
Value
$9.14M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
3/17/2025 | 100K | $2.34M | — | Completed |
2/19/2025 | 9.22K | $182.9K | — | Completed |
2/18/2025 | 90.78K | $1.81M | — | Completed |
1/30/2025 | 13.58K | $289.7K | — | Completed |
1/29/2025 | 56.86K | $1.19M | — | Completed |
1/28/2025 | 25.39K | $547.9K | — | Completed |
1/27/2025 | 104.17K | $2.39M | — | Completed |
| Planned — Approximate Date | ||||
3/26/2025 | 16.54K | $387.2K | Nasdaq | Planned |
| Total | 416.54K | $9.14M | ||